Kenvue Target of Unusually High Options Trading (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) was the recipient of unusually large options trading on Wednesday. Traders acquired 141,054 call options on the stock. This is an increase of approximately 63% compared to the average volume of 86,602 call options.

Institutional Trading of Kenvue

Several institutional investors have recently added to or reduced their stakes in the company. Americana Partners LLC boosted its stake in Kenvue by 2.7% in the 3rd quarter. Americana Partners LLC now owns 94,765 shares of the company’s stock valued at $1,538,000 after purchasing an additional 2,517 shares during the period. Root Financial Partners LLC bought a new stake in Kenvue in the 3rd quarter valued at $70,000. Arkadios Wealth Advisors boosted its stake in Kenvue by 4.1% in the 3rd quarter. Arkadios Wealth Advisors now owns 22,041 shares of the company’s stock valued at $358,000 after purchasing an additional 876 shares during the period. Turtle Creek Wealth Advisors LLC bought a new stake in Kenvue in the 3rd quarter valued at $197,000. Finally, Allstate Corp bought a new stake in Kenvue in the 3rd quarter valued at $1,152,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Bank of America lowered their price target on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. Citigroup lowered their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, October 9th. Barclays lowered their price target on Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 1st. Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $20.17.

Kenvue Stock Down 1.7%

KVUE stock opened at $14.26 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $27.37 billion, a PE ratio of 19.27, a PEG ratio of 2.09 and a beta of 0.72. Kenvue has a 1-year low of $14.05 and a 1-year high of $25.17. The business’s 50 day simple moving average is $17.50 and its 200 day simple moving average is $20.63.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 5.8%. Kenvue’s payout ratio is 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.